Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier
Cédric
C
Evrard
Alexandre
A
Ciccolini
Joseph
J
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology*; D003564:Cytidine Deaminase / Q000097:blood / Q000235:genetics*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D005188:False Negative Reactions; D005838:Genotype; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D011110:Polymorphism, Genetic; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D003564:Cytidine Deaminase; D000093542:Gemcitabine